Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Triple-Blinded, Active-Controlled Study to Assess the Safety and Immunogenicity of an Investigational Herpes Zoster (HZ) Vaccine, JCXH-105, in Healthy Subjects ≥ 50 Years of Age

NCT06581575 is registered in ClinicalTrials.gov with Immorna Biotherapeutics, Inc. as lead sponsor.

NCT NCT06581575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06581575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Triple-Blinded, Active-Controlled Study to Assess the Safety and Immunogenicity of an Investigational Herpes Zoster (HZ) Vaccine, JCXH-105, in Healthy Subjects ≥ 50 Years of Age
Lead sponsor
Immorna Biotherapeutics, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 16, 2024
Completion date
August 31, 2026
Enrollment
467 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

herpes zoster (hz), infectious diseases, shingles